Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that.
Reading a rodent study, and specifically the version of it that the documentation does not cover. The maintained page handles the general case well and stops exactly where my question starts.
Setting out the gap in case it is a gap in the page rather than a gap in what is known.
The arithmetic in the opening post is right; the assumption feeding it is the part to check.
CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
I have kept the units in throughout, for the obvious reason.
An update on my earlier reading a rodent study post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Adding the measurement that post #4 says would settle it.
Trying to state the reading a rodent study position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Post #6 describes the usual case. This is about the unusual one.
Reading a rodent study sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Post #8 is right about the mechanism and I think understates the practical bit.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
It is a small point and it changes the answer, which is an awkward combination.
What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.
Somebody will have a better source than mine, and I hope they post it.
CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.
Nothing to add on the substance. Thank you for taking the question at face value.
Two sentences on reading a rodent study and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
The reason reading a rodent study is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
The pulsatile character of endogenous growth hormone release is why a secretagogue and exogenous growth hormone are not interchangeable, and why a single measured level tells you very little about either.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
Worth separating two things that post #13 runs together.
What I would check first on reading a rodent study is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
Written from notes rather than memory, which is why the numbers are specific.
Picking up post #22: that is the part I would want checked first.
Growth hormone secretagogues act on the ghrelin receptor or on the growth hormone releasing hormone receptor rather than supplying growth hormone, which is the distinction that matters for anyone reading the literature.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
One caution on reading a rodent study: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
This follows post #26 rather than contradicting it.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
A qualification I should have led with rather than closed on.
Worth separating two things that post #24 runs together.
Reading a rodent study is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.